Protein Design Labs
was lower in active trading on Instinet following mixed results in a test for its experimental cancer treatment Zamyl.
The company said the treatment improved patients' response to chemotherapy by 65%, but failed to achieve the trial's primary goal of improving the rate of complete remission after 70 days.
The study was a phase 3 trial of Zamyl in patents with acute myeloid leukemia, a form of blood cancer.
On Instinet, the company's shares were down $2.07, or 5%, to $38.50.